Pune, India – April 20, 2026 – The global dry age-related macular degeneration (AMD) market is projected to experience steady expansion, growing from USD 1.89 billion in 2024 to USD 3.51 billion by 2033, at a CAGR of 7.13% during 2025–2033, according to recent industry analysis.

The growth is primarily attributed to the rising global geriatric population, increasing prevalence of vision disorders, and growing healthcare investments across developed and emerging economies.

📩 Get a FREE Sample PDF — Unlock an Exclusive Discount on the Full Market Report When You Inquire Through: https://straitsresearch.com/report/dry-age-related-macular-degeneration-market/request-sample 

Market Overview

Dry age-related macular degeneration is a progressive eye disorder affecting the macula, the central part of the retina responsible for sharp vision. It is the most common form of AMD, accounting for nearly 90% of diagnosed cases, and primarily affects individuals above the age of 60.

Unlike wet AMD, dry AMD progresses gradually but can still lead to significant central vision loss over time, impacting daily activities such as reading and recognizing faces.

Key Market Highlights

• Market Size (2024): USD 1.89 Billion
• Projected Value (2033): USD 3.51 Billion
• CAGR (2025–2033): 7.13%
• Leading Region: North America
• Fastest Growing Region: Europe
• Key Growth Segment: Intermediate AMD stage
• Dominant Age Group: Above 75 years

Growth Drivers

1. Rapidly Aging Global Population

The increasing elderly population is one of the most significant factors driving market growth. According to global demographic estimates, the population aged 65 and above is expected to nearly double by 2050, significantly increasing the number of individuals at risk of dry AMD.

2. Rising Prevalence of Eye Disorders

Conditions such as diabetes and hypertension are contributing to a higher incidence of retinal diseases, including AMD. The growing burden of vision impairment is increasing demand for diagnostic and management solutions.

3. Increasing Healthcare Spending

Rising global healthcare expenditure is improving access to ophthalmic care, diagnostic tools, and nutritional therapies that help slow disease progression.

📩 Get a FREE Sample PDF — Unlock an Exclusive Discount on the Full Market Report When You Inquire Through: https://straitsresearch.com/report/dry-age-related-macular-degeneration-market/request-sample 

Market Challenges

Despite strong growth prospects, the market faces several challenges:

• Lack of approved curative treatments for dry AMD
• High failure rates in clinical trials
• Strict regulatory approval processes for new therapies
• Delays in drug commercialization impacting revenue growth

These factors continue to limit the availability of effective treatment options and slow market expansion.

Opportunities in Pipeline Therapies

Ongoing research and development efforts are creating new opportunities in the dry AMD space. Several pipeline drugs targeting complement system inhibition, retinal protection, and inflammation control are currently under clinical evaluation.

Recent advancements, including FDA approvals in related geographic atrophy treatments, are expected to accelerate innovation and improve future treatment outcomes.

Regional Analysis

North America

North America holds the largest market share, driven by high disease prevalence, advanced healthcare infrastructure, and strong awareness of retinal disorders. The United States represents a major contributor due to its large aging population and increasing ophthalmology care utilization.

Europe

Europe is expected to witness strong growth due to its rapidly aging population and increasing adoption of advanced diagnostic technologies. Government initiatives and improved healthcare access further support market expansion.

Asia-Pacific

Asia-Pacific is emerging as the fastest-growing region, supported by increasing healthcare investments, rising awareness of eye health, and expanding elderly population in countries such as China and India.

Competitive Landscape

Key players operating in the global dry age-related macular degeneration market include:

• Apellis Pharmaceuticals, Inc.
• Astellas Pharma Inc. (Iveric Bio)
• Hoffmann-La Roche AG (Genentech, Inc.)
• Ionis Pharmaceuticals
• Disc Medicine, Inc.
• NGM Biopharmaceuticals
• Annexon Biosciences
• AstraZeneca (Alexion Pharmaceuticals)
• Novartis AG
• Biogen

These companies are actively focusing on clinical trials, pipeline expansion, and strategic collaborations to strengthen their market presence.

Future Outlook

The dry AMD market is expected to grow steadily over the forecast period, supported by increasing aging population trends, improved diagnostic capabilities, and continued advancements in retinal disease research. While challenges remain in drug development, ongoing innovation is expected to improve treatment availability in the coming years.

https://sites.google.com/view/consumerandpackageingresearchr/home/ornamental-fish-market-size

https://straitsreseachtrendingreports.blogspot.com/2026/04/ornamental-fish-market-to-reach-usd.html